Skip to Main Content
Services Talent Knowledge
Site Search
Menu

Blog Post

January 29, 2021

A Look at the State and Federal Rollercoaster That Is PBM Reform—Post-Rutledge and Post-Election

Following the US Supreme Court’s decision in Rutledge and a change in presidential administration, reform of pharmacy benefit managers (PBMs) and their role in the marketplace has gained significant traction at the state and federal levels.

Federally, the Biden administration is confronted with whether to proceed with a final rule published by the Trump administration that creates two new safe harbors governing certain pharmaceutical manufacturer price reductions at the point of sale as well as PBM fees. The final rule also removes discount safe harbor protection for rebates under the Anti-Kickback Statute by excluding rebates from the definition of a discount.

On Inauguration Day, President Biden issued a memorandum detailing how his administration plans to manage the federal regulatory process. Concerning rules that have been published in the Federal Register, but have not yet taken effect, the administration asked heads of executive departments and agencies to consider postponing the rules’ effective dates for 60 days from January 20, 2021. The new safe harbors to the Trump administration’s “no rebate” final rule take effect as of January 29, 2021; the removal of the discount safe harbor is delayed until January 1, 2022. Whether the Biden administration’s Department of Health and Human Services intends to adopt the final rule and defend its validity against the recent lawsuit filed by the Pharmaceutical Care Management Association (PCMA) remains to be seen. Assuming stakeholders are afforded notice with a comment period following any changes to or rescission of the final rule, certain causes of action asserted by the PCMA could be considered moot. As a practical matter, Biden’s administration will be compelled to limit skyrocketing drug prices, as pharmaceutical companies increased prices on hundreds of prescription drugs at the beginning of 2021.   

Meanwhile, New York’s Executive Budget for fiscal year 2020-21 requires PBMs to register and become licensed by the Department of Financial Services (DFS). DFS may set minimum standards for issuance of a PBM license, including standards of conduct that may address things like prohibitions on anticompetitive conduct and spread pricing. DFS also has the authority to suspend, revoke, or refuse to renew or issue a PBM license if its determines that the PBM violated, among other things, state insurance law. Amid these significant changes, independent pharmacies and other stakeholders will hopefully be provided with greater transparency in drug pricing and other reimbursement-related issues.

Barclay Damon represents independent pharmacies and other stakeholders across the United States. Its attorneys actively monitor the constantly evolving landscape of PBM reform and are experienced in handling issues arising out of stakeholder relationships with PBMs.

If you have any questions about this blog post, please contact Linda Clark, Health Care Controversies Practice Area chair, at lclark@barclaydamon.com; Mary Connolly, associate, at mconnolly@barclaydamon.com; Brad Gallagher, partner, at bgallagher@barclaydamon.com; or another member of the firm’s Health Care Controversies Practice Area.

Featured Media

Alerts

COVID-19 Business Interruption Update: New York High Court Affirms in Favor of Insurer

Alerts

USFWS Introduces General Permit for Bald and Golden Eagle Incidental Take

Alerts

ORES Executive Director Issues First Denial of Section 94-C Permit Application Following Applicant's Partial Loss of Site Control

Alerts

New Details About OPWDD Spending in the New York State FY 2025 Executive Budget

Alerts

Second Circuit Reverses in Favor of Insured in $600,000 Fire Loss Case

Alerts

New York State Minimum Wage Increases Are Here: Are You Compliant?

We're Growing in DC!

We’re excited to announce Barclay Damon’s combination with Washington DC–based Shapiro, Lifschitz & Schram. SLS’s 10 lawyers, three paralegals, and four administrative staff will join Barclay Damon while maintaining their current office in DC’s central business district. Our clients will benefit from SLS’s corporate, real estate, finance, and construction litigation experience and national energy-industry profile, and their clients from our full range of services.

Read More

This site uses cookies to give you the best experience possible on our site and in some cases direct advertisements to you based upon your use of our site.

By clicking [I agree], you are agreeing to our use of cookies. For information on what cookies we use and how to manage our use of cookies, please visit our Privacy Statement.

I AgreeOpt-Out